487 related articles for article (PubMed ID: 17914985)
1. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.
Kitamura K; Tada S; Nakamoto N; Toda K; Horikawa H; Kurita S; Tsunematsu S; Kumagai N; Ishii H; Saito H; Hibi T
J Gastroenterol Hepatol; 2007 Nov; 22(11):2022-33. PubMed ID: 17914985
[TBL] [Abstract][Full Text] [Related]
2. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Kudo H; Yata Y; Takahara T; Kawai K; Nakayama Y; Kanayama M; Oya T; Morita S; Sasahara M; Mann DA; Sugiyama T
Liver Int; 2009 Aug; 29(7):988-96. PubMed ID: 19386026
[TBL] [Abstract][Full Text] [Related]
5. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.
Kawaguchi K; Sakaida I; Tsuchiya M; Omori K; Takami T; Okita K
Biochem Biophys Res Commun; 2004 Feb; 315(1):187-95. PubMed ID: 15013444
[TBL] [Abstract][Full Text] [Related]
8. Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice.
van Beuge MM; Prakash J; Lacombe M; Gosens R; Post E; Reker-Smit C; Beljaars L; Poelstra K
J Pharmacol Exp Ther; 2011 Jun; 337(3):628-35. PubMed ID: 21383021
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
[TBL] [Abstract][Full Text] [Related]
10. IFN-γ deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine- and choline-deficient high-fat diet.
Luo XY; Takahara T; Kawai K; Fujino M; Sugiyama T; Tsuneyama K; Tsukada K; Nakae S; Zhong L; Li XK
Am J Physiol Gastrointest Liver Physiol; 2013 Dec; 305(12):G891-9. PubMed ID: 24136786
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.
Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Fukui H
Hepatology; 2001 Oct; 34(4 Pt 1):745-50. PubMed ID: 11584371
[TBL] [Abstract][Full Text] [Related]
12. Rho-kinase inhibitor targeting the liver prevents ischemia/reperfusion injury in the steatotic liver without major systemic adversity in rats.
Kuroda S; Tashiro H; Kimura Y; Hirata K; Tsutada M; Mikuriya Y; Kobayashi T; Amano H; Tanaka Y; Ohdan H
Liver Transpl; 2015 Jan; 21(1):123-31. PubMed ID: 25307969
[TBL] [Abstract][Full Text] [Related]
13. Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats.
Yamada T; Kuno A; Masuda K; Ogawa K; Sogawa M; Nakamura S; Ando T; Sano H; Nakazawa T; Ohara H; Nomura T; Joh T; Itoh M
J Pharmacol Exp Ther; 2003 Oct; 307(1):17-23. PubMed ID: 12944495
[TBL] [Abstract][Full Text] [Related]
14. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat.
Li X; Meng Y; Wu P; Zhang Z; Yang X
Regul Pept; 2007 Jan; 138(1):15-25. PubMed ID: 16971004
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.
Sahai A; Malladi P; Melin-Aldana H; Green RM; Whitington PF
Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G264-73. PubMed ID: 15044174
[TBL] [Abstract][Full Text] [Related]
17. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats.
Yamada T; Kuno A; Ogawa K; Tang M; Masuda K; Nakamura S; Ando T; Okamoto T; Ohara H; Nomura T; Joh T; Shirai T; Itoh M
J Pharmacol Exp Ther; 2005 Apr; 313(1):36-45. PubMed ID: 15608084
[TBL] [Abstract][Full Text] [Related]
19. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Toblli JE; Muñoz MC; Cao G; Mella J; Pereyra L; Mastai R
Obesity (Silver Spring); 2008 Apr; 16(4):770-6. PubMed ID: 18239590
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
Zhang W; Wu R; Zhang F; Xu Y; Liu B; Yang Y; Zhou H; Wang L; Wan K; Xiao X; Zhang X
Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):1026-33. PubMed ID: 23127227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
